Part II: Chemotherapy for epithelial ovarian cancer - treatment of recurrent disease

被引:122
作者
Harries, M [1 ]
Gore, M [1 ]
机构
[1] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England
关键词
D O I
10.1016/S1470-2045(02)00847-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For women with advanced ovarian cancer, rates of response to first-line chemotherapy are high but most patients have relapses and become candidates for further chemotherapy. Chemotherapy for recurrence can palliate symptoms, and there is some evidence that it can also improve survival in this clinical situation. Patients who relapse quickly after first-line therapy should not be given the same drugs as were used initially. However, for patients who have longer intervals from treatment to relapse, the rates of response to a rechallenge with platinum are clinically significant. Several cytotoxic drugs have shown activity in patients whose disease has relapsed after therapy with platinum and a taxane; these drugs include topotecan, etoposide, pegylated liposomal doxorubicin, epirubicin, gemcitabine, altretamine, oxaliplatin, and vinorelbine. Recurrent ovarian cancer is also an important setting in which to test investigational agents with promising activity, such as new platinum compounds, new taxanes, and other cytotoxic agents, as well as non-cytotoxic compounds with novel mechanisms of action.
引用
收藏
页码:537 / 545
页数:9
相关论文
共 78 条
[31]  
HATCH KD, 1991, CANCER, V68, P269, DOI 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO
[32]  
2-O
[33]   PHASE-II TRIAL OF INTRAVENOUS HEXAMETHYLMELAMINE IN PATIENTS WITH ADVANCED OVARIAN-CANCER [J].
HAUGE, MD ;
LONG, HJ ;
HARTMANN, LC ;
EDMONSON, JH ;
WEBB, MJ ;
SU, J .
INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) :299-301
[34]  
Hay M P, 2000, Curr Opin Investig Drugs, V1, P263
[35]  
Hellström I, 2001, CANCER RES, V61, P2420
[36]  
Hirte H.W, 2001, P AN M AM SOC CLIN, V20, p211a
[37]   Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy [J].
Hochster, H ;
Wadler, S ;
Runowicz, C ;
Liebes, L ;
Cohen, H ;
Wallach, R ;
Sorich, J ;
Taubes, B ;
Speyer, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2553-2561
[38]   Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group Study [J].
Hoskins, P ;
Eisenhauer, E ;
Beare, S ;
Roy, M ;
Drouin, P ;
Stuart, G ;
Bryson, P ;
Grimshaw, R ;
Capstick, V ;
Zee, B .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2233-2237
[39]   Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J].
Huinink, WTB ;
Gore, M ;
Carmichael, J ;
Gordon, A ;
Malfetano, J ;
Hudson, I ;
Broom, C ;
Scarabelli, C ;
Davidson, N ;
Spanczynski, M ;
Bolis, G ;
Malmstrom, H ;
Coleman, R ;
Fields, SC ;
Heron, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2183-2193
[40]  
Joly F., 2002, P AN M AM SOC CLIN, V21, p202a